Introduction and initial discovery of endothelial progenitor cells (EPCs)
By the early 1950s, human patients with cardiovascular disease were having diseased segments of large blood vessels replaced by artificial vascular grafts, which upon later excision were covered in a layer of endothelial cells (ECs). 1, 2 It was assumed that the endothelium observed on these vascular grafts grew from the original vessel ends at the site of anastomosis, and any patches of endothelium discontinuous with this endothelium arose from microvasculature penetrating the interstices of the graft (perhaps through development of vaso vasorum).
1, 3 Stump et al. 4 directly addressed the question of whether circulating cells would colonize an artificial substrate implanted intravascularly by suspending a piece of Dacron material within a pig aortic graft, thereby isolating the surface of the Dacron material from any opposing microvasculature. After 14 days in the animal, they observed patches of endothelium on the graft, and by 20 days, the graft segment was completely lined by endothelium (identified with silver nitrate staining). The authors concluded that circulating endothelium must have attached and proliferated to cover the suspended material. Gaynor et al. 5 measured the number of circulating endothelial cells (CECs) in the blood of rabbits administered a dose of endotoxin, and reported an increase in the CEC concentration, which suggested that CECs could serve as a marker to measure vascular injury. Indeed, CEC concentrations have been found to be altered in patients with a variety of vascular injury and disease, including coronary angioplasty, 6 acute coronary syndromes and unstable angina, 7 peripheral vascular disease, 8 and inflammatory vasculitis, 9 when conditioning for bone marrow transplantation, 10 and during organ transplant rejection. 11 More recently, CECs have been measured by CD146 expression, and changes in the concentration of CD146 þ cells have been used as a biomarker for many human disorders. 12 The concentration of CECs in the blood of normal human subjects is low, typically about three cells per ml, but this number may significantly increase in many disease states. [13] [14] [15] Prior to 1997, the predominant paradigm for new vessel formation in adult subjects was believed to be endothelial sprouting from pre-existing vessels, and regional hypoxia was believed to be abated through a process termed angiogenesis. 16 In 1997, Asahara et al. 17 purified a population of circulating cells which displayed properties of both ECs and progenitor cells. Termed 'endothelial progenitor cells' (EPCs), they were purported to give rise to differentiated ECs in a process termed postnatal vasculogenesis. 17 Before this seminal contribution, vasculogenesis was thought to occur only in the developing fetus when progenitors of endothelium (angioblasts) differentiate to form nascent vessels in developing tissues. [18] [19] [20] The de novo formation of vessels from uncommitted precursors sets vasculogenesis apart from both angiogenesis and arteriogenesis. 19 It now appears that aside from angiogenesis and arteriogenesis, circulatory system remodeling in the adult may indeed involve the recruitment of not only endothelial progenitors but also a plurality of cells in an intricate collaboration. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Sprouted endothelium may line the vessel lumen while other cells support vessel formation through secretion of cytokines and modification of the extracellular space. [40] [41] [42] [43] [44] [45] Although each cell type appears to be fundamentally different, all cell types involved in postnatal vasculogenesis have been lumped into the single term 'EPC'. Here, we attempt to clarify study results by closely examining and comparing the methods used to define different cell populations and in the end, propose some unifying working hypotheses.
EPC definition and characterization -colony-forming unit-EC
EPCs represent a minor subpopulation of blood mononuclear cells (MNCs), and in vitro cell culture methods have been developed to select and expand this population. In general, three culture methods for isolating EPCs have been described (Figure 1 ). The original method by Asahara et al., 17 which has subsequently been modified, 46, 47 can now be performed using a commercially available kit (Figure 1a ; Method A) (Endocult, StemCell Technologies, Vancouver, British Columbia, Canada).
In this method, adult peripheral blood (PB) or human umbilical cord blood (CB) MNCs are plated on fibronectin-coated dishes. After a 48 h pre-plating step to deplete the sample of adherent macrophages and mature ECs, the non-adherent cells are removed and re-plated on fibronectin-coated dishes. Discrete colonies emerge in 5-9 days, comprised of round cells centrally with spindle-shaped cells sprouting at the periphery. To avoid confusion, colonies of this type are now widely referred to as colony-forming unit-ECs (CFU-ECs) or colony-forming unit-Hill (CFU-Hill) cells. 46 Asahara et al. 17 reported that CFU-EC colonies could be cultured from a heterogeneous MNC population enriched for either the stem cell marker CD34 or vascular endothelial growth factor receptor-2 (VEGFR-2) expression. Some of the fibronectinadherent cells (15.7%) expressed CD34, and in this population, CD45 expression was gradually lost (94% were initially positive for CD45), 27% were Flk-1 (vascular endothelial growth factor receptor) positive, and 11% were doubly positive for CD34 and Flk-1. EPC expression of CD34, CD31, Flk-1, Tie-2, and E-selectin was greater after 7 days of culture than in freshly isolated CD34 þ cells, leading Asahara et al. 17 to conclude that the cultured cells displayed an endothelial phenotype. Populations of MNCs enriched for Flk-1 were reported to behave similarly to the CD34-enriched MNCs. Furthermore, injection of freshly isolated MNCs from adult PB (enriched to 15.7% CD34-positive cells) into nude mice with induced hind limb ischemia led to apparent engraftment of human cells in 13.4% of the mouse capillaries in the injured extremity. Thus, the conclusion was drawn that circulating CD34 þ or Flk-1 þ MNCs from adult PB contributed to new vessel formation via postnatal vasculogenesis and that the culture conditions yielded colonies of the cells responsible. 
SPOTLIGHT
Hill et al. 46 employed the CFU-EC assay to relate circulating EPC concentration to cardiovascular disease susceptibility and observed a decrease in CFU-EC colonies from patients with increased Framingham risk factor score. Additionally, the concentration of CFU-ECs was lower in the PB of patients with elevated cholesterol, hypertension, and type II diabetes. Statistical analysis revealed that not only was CFU-EC concentration altered, but that the CFU-EC concentration reflected vascular health, since brachial artery reactivity increased with increasing CFU-EC concentration. Later studies demonstrated that the concentration of CFU-ECs was decreased in patients with type I diabetes, 48 chronic obstructive pulmonary disease, 49 congestive heart failure, 50 and rheumatoid arthritis. 51 However, some studies have contradicted the trend of lower numbers in disease susceptibility; CFU-EC concentration has been shown to be significantly increased in patients with unstable angina, 52 at the time of myocardial infarction (MI), 53 and within 7 days of an acute MI. 54 Thus, evidence points to reduced CFU-EC concentration in patients at risk for vascular disease, and increased during acute cardiovascular stress. These observations have contributed to the hypothesis that circulating EPCs may be protective against development of certain diseases of the cardiovascular system. Consistent with the protective hypothesis, CFU-ECs have been administered as a potential cell therapy to promote angiogenesis in pre-clinical animal models of vascular and myocardial ischemia (reviewed elsewhere [55] [56] [57] [58] ). The general conclusion of the many studies that have infused cultured EPCs, or select populations of circulating cells, into various animal models of vascular disease, is that EPCs may be therapeutic. However, the results of EPC infusion from several human clinical trials have not yet revealed the same level of efficacy as pre-clinical animal studies predicted.
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EPC definition and characterization -circulating angiogenic cell
In another widely employed and methodologically similar approach ( Figure 1 , Method B), whole, unfractioned MNCs are cultured in supplemented endothelial growth media for 4 days, whereupon the non-adherent fraction of cells are removed, resulting in a target adherent cell population. [65] [66] [67] The resulting culture of cells display features of an endothelial phenotype and function through binding of the endothelial-specific lectin Ulex Europeus Agglutinin-1 (UEA-1), and uptake of acetylated low-density liproprotein (acLDL). 66, 67 The cells express von Willebrand factor (vWF), platelet-endothelial cell adhesion molecule (PECAM-1 or CD31), VEGFR-2, vascular endothelial cadherin (VE-cadherin or CD144), Tie-2/TEK (angiopoietin-1 receptor precursor or tunica intima endothelial cell kinase), and bind Bandeiraea simplicifolia lectin (BS-1). [65] [66] [67] [68] [69] Upon review, these cells appear similar to CFU-ECs in surface marker expression and in vitro function, and as a result, both have often been grouped together in the literature under the title EPCs. However, these adherent cultured cells have also been referred to as circulating angiogenic cells (CACs) in recognition that these cells appear to promote neovascularization in animal models of critical limb ischemia or MI. 67, [70] [71] [72] Interestingly, CACs do not display the colony morphology of CFU-ECs though the sprouting spindle-shaped cells from CFUECs are similar in shape to CACs in culture. 65, 67 Furthermore, CACs can be collected from culture in far greater numbers than CFU-ECs, comprising approximately 2% of the whole MNC population. 65 Changes in CAC concentration parallel the observed trends of CFU-EC concentration in patients with cardiovascular disease and risk, which provides further support for the EPC protective hypothesis. [72] [73] [74] [75] [76] [77] [78] Vasa et al. 73 observed that as the number of risk factors for coronary artery disease (CAD) increased (including age, sex, hypertension, diabetes, smoking, family history, and low-density lipoprotein (LDL) cholesterol levels), the CAC concentration in PB decreased, with smoking being the most significant risk factor for low CAC concentration. Vasa et al. 73 also included a comparison of migratory activity of CACs to individual CAD risk factors. Subsequent multivariate analysis revealed hypertension to be the greatest risk factor associated with arrested CAC migration. 73 Lambiase et al. 76 corroborated the relationship between circulating PB CAC concentration and clinically diagnosed CAD, finding that the CAC concentration was reduced by 70-75% when examining the extent of collateral coronary vessel development in 30 patients with left anterior descending CAD. In other studies, severity of type II diabetes correlated with the concentration of CACs, 78 as did hemodialysis, 75 further indicating a potentially protective role for circulating EPCs. Finally, CAC concentration has been shown to increase immediately after exercise, 72 upon acute exercise-induced myocardial ischemia, 77 and higher levels can be maintained with repeated exercise-induced myocardial ischemia. 74 Cultured human CACs have been infused into patients following acute MI in the TOPCARE-AMI clinical trial by Assmus et al., 59, 79 and results indicated limited efficacy following the intracoronary cell infusion. 59, 79 In contrast, numerous animal models of acute MI revealed a promising therapeutic benefit of infusing CACs. [55] [56] [57] [58] This discrepancy has not yet been explained.
EPC definition and characterization -endothelial colony forming cells
The least studied of all EPC types are now termed 'endothelial colony-forming cells' (ECFCs). ECFCs are derived using methods similar to those originally reported for endothelial outgrowth from PB ( Figure 1, Method C) . 80 In this method, adult PB MNCs or human umbilical CB MNCs are collected and plated onto collagen I-coated plates in endothelial-specific growth media. 39, 81 Non-adherent cells are discarded during gentle washing steps. 80 ECFC colonies emerge from the adherent cell population 10-21 days after plating (5-7 days if human umbilical CB MNCs are plated) and display a cobblestone appearance typical of ECs (Figure 1c) . 39, 81, 82 Thus far, ECFCs have proven to be phenotypically indistinguishable from cultured ECs, and posses de novo vessel-forming ability. 39, 81, 82 Because ECFCs emerge much later in culture as compared to both CFU-ECs and CACs, ECFCs have been called 'late outgrowth' EPCs, while CFU-ECs and CACs have been called 'early outgrowth' EPCs; 31, 83, 84 however, it may no longer be appropriate to use this terminology as it does not accurately identify the various EPCs.
If circulating EPCs are to be defined as true progenitor cells with postnatal vasculogenic potential, then evidence should be presented that human EPCs proliferate at a clonal level, and that human EPCs will give rise to differentiated progeny with de novo vessel formation when implanted in vivo. 85 To address the first point, our group reported that single ECFCs have significant potential for clonogenic expansion, and in fact display a hierarchy of proliferative potentials similar to the HPC hierarchy. 81 A novel method was developed to permit seeding of single cells into culture and conditions were optimized to enumerate the colonies of ECs that frequently emerged. The colonies were then serially replated to assess for replating potential. A complete hierarchy of human ECFCs was determined and human umbilical CB was found to be enriched with ECFCs displaying high proliferative potential (HPP-ECFC). Subsequently, we also elucidated this hierarchy in single-plated ECs freshly isolated from human umbilical veins (HUVECs).
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The observation that the ECFC hierarchy exists in HUVECs provides support for the concept that the vessel intima contains ECs which are capable of repopulating the intima, and may be a reservoir for mobilizing circulating ECFC. 86 These resident ECFCs may represent the primary source of endothelium for angiogenesis. 86 In the hematopoietic system, stem cells differ from progenitor cells by displaying the ability to self-renew and repopulate the hematopoietic system upon transplantation into a conditioned recipient subject. 87, 88 We hypothesized that the most definitive method to assay for postnatal vasculogenesis would be to suspend putative EPCs in a scaffold, implant the scaffold, and assay for de novo human vessel formation. Following the work of Schechner et al., 89, 90 we established a de novo EPC differentiation model in NOD/SCID mice. 39, 89, 90 In this model, collagen I gels are mixed with EPC test cells and implanted into immunodeficient mice. Upon scaffold excision 14 days later, the number and histological characteristics of human vessels are examined. We have reported that ECFCs will undergo de novo vessel formation in this in vivo collagen gel-based assay. 39 In many of the scaffolds, ECFC-derived vessels inosculate with host murine vessels and function as a conduit for the murine blood through the implanted gels. 39 In the same assay, CFU-ECs have never formed vessels. 39 These data have led us to conclude that ECFCs display the features consistent with the term EPC.
Data to corroborate the role of ECFCs in vascular homeostasis and repair have only recently become available. Guven et al. 91 cultured both CACs and ECFCs in parallel from patients with varying degrees of coronary stenosis. In this study, 48 patients were classified as to disease severity based on angiographic stenosis, and the concentration of circulating PB ECFCs and CACs were correlated with disease severity. Interestingly, both ECFCs and CACs were found to increase in concentration in relation to the severity of CAD; the patients with the most severe CAD were shown to have the highest circulating EPC concentrations, contradicting the results of similar studies. 46, 76, 92 To our knowledge, this remains one of only a few studies to date which has examined circulating ECFC concentrations in a human pathological condition. 80 
EPC definition and characterization -by fluorescenceactivated cell sorter analysis
Cell culture methods utilized for identifying EPCs not only isolate but may also expand the circulating EPCs that are normally found in the blood. When using cell culture to define and characterize EPCs, the starting cell population is typically heterogeneous, making it difficult to determine the precursor cell giving rise to the EPCs. Alternatively, EPCs can be prospectively identified without the need for culture, by selecting sub-populations of MNCs based on specific cell surface antigen expression. By utilizing cell surface antigens as markers for EPC definition and characterization, this allows for the selection of a more homogenous population. However, the definition of EPCs via this method is complex due to the absence of any unique and restricted markers for EPCs versus CECs. The effort to accurately characterize EPCs is further confounded due to the considerable overlap observed between cell surface antigens expressed on the surface of putative EPCs and those expressed on cells of the hematopoietic lineage. [93] [94] [95] For example, while the cell surface antigens CD34, CD133, and VEGFR-2 are utilized to identify EPCs, it is also important to note that they are expressed on human hematopoietic stem cells (HSCs), as well as various sub-populations of HPCs, including low proliferative potential (LPP)-and high proliferative potential-colony forming cells (HPP-CFCs). 69, 87, [92] [93] [94] [95] [96] [97] Human circulating EPCs have typically been identified as cells expressing CD34, CD133, and VEGFR-2.
69,98-101 Peichev et al. 99 reported that mature ECs do not express CD133, and that nearly all the CD34 þ VEGFR-2 þ circulating EPCs in mobilized PB, human umbilical CB, and fetal liver express CD133. 99 Furthermore, the CD34 þ VEGFR-2 þ cells were shown to express the chemokine receptor CXCR4, and migrate in response to vascular endothelial growth factor (VEGF) or stromal-derived factor-1 (SDF-1), in vitro. In addition, culture of CD34 þ cells from human fetal liver with VEGF and fibroblast growth factor-2 (FGF-2) resulted in differentiation of nonadherent cells into adherent CD133
À VEGFR-2 þ acetylated LDL þ cells with an EC morphology. 99 The surface of implanted human left ventricular assist devices was reported to be colonized with CD133 þ VEGFR-2 þ cells. 99 These data suggested that the circulating CD34 þ cells co-expressing CD133 and VEGFR-2 are a functionally distinct population of EPCs that may play a role in neoangiogenesis.
Flow cytometry may also be utilized to investigate and enumerate the EPC concentration in the blood of patients at risk for, or with clinical diagnosis of, vascular disease. As previously mentioned, a widely accepted definition for the most primitive EPC precursor in the circulating MNC population is a cell which co-expresses CD34, CD133, and VEGFR-2. 69, [99] [100] [101] In fact, this EPC definition has formed the basis of many clinical studies designed to determine the role of EPCs in a variety of vascular disorders. 60, 100, 102, 103 Specifically, numerous papers have correlated the concentration of CD34
þ cells with the risk of development of adverse cardiovascular outcomes, and in general, an inverse correlation with each of these subsets and the highest risk category exists, 60, 100, 102, 103 which is also in line with alterations observed with CFU-EC and CAC concentrations. Thus, enumeration of CD34 þ CD133 þ VEGFR-2 þ cells in adult PB appears to also serve as a predictor for patient cardiovascular risk, 60, 100, 102, 103 although the biologic mechanism for this observation may be unclear, especially given possible limitations on the precise functional phenotype of circulating
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Hematopoietic characteristics of EPCs
Since monocytes and macrophages have been reported to mimic ECs in vitro, 104 and since CFU-ECs and CACs can be cultured from isolated monocytes/macrophages, 83,105 some controversy has arisen that the CFU-EC and CAC assays may not predict for EPCs but may in fact identify monocytes/ macrophages. Rehman et al. 71 reported evidence for this hypothesis. Rehman et al. 71 observed hematopoietic surface antigen expression and monocyte/macrophage cytokine secretion by CACs. Many others have also suggested that EPCs may be derived from monocytes and macrophages. 104, [106] [107] [108] Recently, Zhang et al. 108 cultivated CACs that displayed features of monocytes and macrophages throughout the culture period, despite upregulation of endothelial nitric oxide synthase (eNOS), VEGFR-2, VE-cadherin, and E-selectin expression (thought to be specific endothelial markers). Surprisingly, the adherent CAC progeny ingested India ink, consistent with macrophage phagocytic activity. 108 Additionally, our group 39 has reported that CFU-ECs actively phagocytose Escherichia coli, display non-specific esterase activity, and express the colony-stimulating factor 1 receptor (CSF-1R), each of which is generally restricted to monocytes and macrophages. Furthermore, CFU-EC colonies fail to differentiate into true endothelial colonies. 39 However, secondary CFU-GM colonies will form from isolated CFU-EC colonies. 39 Additionally, the number of CACs able to be isolated from MNCs (2% of the MNC population) is very near the total number of monocytes in blood (5% of the MNC population). 65, 109 While the cell surface antigen characteristics, angiogenic factor production, and in vitro and in vivo functions of the different types of EPCs can be compared, several important comparative questions remain. For example, are these rare circulating cells derived from a common precursor? Do they possess similar in vivo vessel-forming capacity? Are CFU-ECs and ECFCs derived from the HSC?
Clonal relationship of EPCs to HSCs
In the original description of CFU-ECs by Asahara et al., 17 27.2% of the cultured cells retained CD45 expression and 6% expressed the hematopoietic antigen CD68. Hematopoietic antigen expression in the primary culture was taken as an indication for a relationship between CFU-ECs and HSCs. 17 Grant et al. 110 proposed that any common precursor for both hematopoietic and endothelial lineages might be evaluated in long-term repopulating HSC transplant studies. 110 Transplanting single HSCs into animals that were subsequently administered retinal injury, Grant et al. 110 observed that some of the neoangiogenic vessels formed after injury to the retinal vasculature were derived from the donor stem cells. These results led Grant et al. 110 to conclude that hemangioblasts persist into adulthood, and that these cells are derived from the same HSCs that provide long-term hematopoietic repopulating ability. In humans, Cogle et al. 111 utilized the same murine retina injury model but preceded the retina injury with transplants of human umbilical CB-derived CD34 þ cells, which again repopulate the murine hematopoietic system. Cogle et al. 111 noted human donor cells contributing to the murine host neovasculature, and speculated that only hematopoietic cell progenitors contribute to blood reconstitution and blood vessel repair.
Gunsilius et al. 112 utilized PB or BM from patients suffering from chronic myelogenous leukemia (CML), a known clonal HSC disorder, to examine the clonal origins of EPCs. CML is characterized by a unique chromosomal translocation, t (9;22) , that results in a BCR/ABL fusion gene product. 113 This translocation is present in a multi-potent HSC clone and all the derived progeny. 113 This feature permitted Gunsilius et al.
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to examine EPCs for this genetic mutation. They reported that in five of six patients, cultured CFU-ECs displayed the translocation, suggesting to Gunsilius et al. 112 that EPCs arise from a hemangioblastic precursor. To assay for the hematopoietic BCR/ ABL fusion gene in vasculature, the endothelium of myocardial blood vessels were examined by fluorescence in situ hybridization. A single CML patient indicated that some ECs in the heart displayed the translocation, although no other support for hematopoietic origin was provided from other patient samples.
To our knowledge, no additional clonal CML data have since corroborated this single report.
Similarly to the BCR/ABL fusion gene, the JAK2 V617F mutation has recently been described in human myeloproliferative disorders, thereby providing another genetic marker for clonal analysis. 114 Using cells obtained from a patient with polycythemia vera, known to bear the JAK2 V617F mutation, as well as cells from a patient with chronic idiopathic myelofibrosis (who had been found to carry trisomy 8 in both unstimulated PB and BM), Oppliger Leibundgut et al. 115 also set out to determine the origin of EPCs. Utilizing hematopoietic CFU assays and the CFU-EC assay, Oppliger Leibundgut et al. 115 obtained endothelial colony growth in parallel to hematopoietic growth. The presence of genetic markers (i.e., trisomy 8 and the JAK2 V617F mutation) in both lineages was sufficient evidence to conclude the hematopoietic origin of CFU-ECs, corroborating the data of Gunsilius et al. 112 However, this study did not examine mature vessel endothelium for evidence of the mutation.
Our group has reported a parallel clonal analysis of ECFCs and CFU-ECs in human subjects with the clonal HSC disorder polycythemia vera. 39 We utilized the JAK2 V617F mutation of individual patients with polycythemia vera to determine the clonal relationship of ECFCs to CFU-ECs and the mutated hematopoietic system. 39 From the blood of 11 patients, both CFU-ECs and ECFCs were cultured, and in all 11 patients the mutation was present in CFU-EC, proving that CFU-EC are descendents of the HSCs. In contrast, ECFCs from 10 of the same 11 patients did not show the mutation. Thus, we concluded that ECFCs are not hematopoietic in origin. In one patient, three ECFC colonies displayed the mutant JAK2 allele. These data could be interpreted as support for a hemangioblast precursor for hematopoietic and ECFC lineages, a unique germline mutation (not yet observed in any polycythemia vera (PV) patients), or contamination of the ECFC by hematopoietic MNCs. Thus, additional clonal analysis may be required in a larger cohort of patients to draw definitive conclusions regarding the clonal relationship of HSCs and ECFCs.
Summary
Given the complexity of the nomenclature in the field of EPCrelated research, and the different features and origins of the cells involved in repair of the vasculature, we offer our interpretations in a unifying set of novel hypotheses. The vast majority (499.99%) of CD45 þ MNCs are hematopoietic elements (Figure 2) . 109 A major portion of circulating mononuclear phagocytes, which constitute roughly 5% of PB MNCs, has possibly been termed CACs, and thus, EPCs. Although a critically important cell to the healing process, 22, 27 we hypothesize that CACs constitute a heterogeneous population of mostly differentiated myeloid cells. The detailed profile of cells within CAC cultures has not yet been reported, but CACs have been reported to constitute a robust 2% of all blood MNCs. 65 In contrast, a diminishingly small fraction of blood MNCs, roughly 80-800 cells/ml of adult PB, are CD45 þ hematopoietic progenitors, 109 a fraction roughly equal to the number of CD45 þ CFU-ECs found in adult PB (in the range of 50-500 cells/ml of adult PB). 39 CFU-ECs are hematopoietic by clonal lineage tracking, a feature likely to be shared by CACs. 39, 112 We also propose that ECFCs display all the properties of a circulating endothelial progenitor. 86 We have reported that ECFCs reside throughout the vascular endothelium, 82 and
SPOTLIGHT
hypothesize that these ECFCs may mobilize to become a subset of CECs, as presently defined 86 ( Figure 2 ). Enriched in human umbilical CB as compared to adult PB, ECFCs are found at a concentration of about 2-5 cells/ml in human umbilical CB, and at a concentration of about 0.05-0.2 cells/ml in adult PB, 81 whereas CECs occur at a frequency of 3 cells/ml in adult PB 12 ( Figure 2 ). In adult human subjects, ECFCs appear to arise independent of hematopoietic precursors. 39 Based on this working hypothesis, we believe the majority of work conducted in the field of EPC replacement therapy has been focused on cells that do not give rise to the vessel, but which recruit or facilitate the cells that do. Recruitment has emerged as a critically relevant step in the healing process, which can be illustrated by the vast number of inflammatory cells at sites of ischemic injury, including the involvement of myeloid cells at those sites. 16, 116, 117 Further research is required to link the processes involved in the recruitment of hematopoietic elements necessary for vascular repair, to endothelial progenitor recruitment from either the vessel wall or the circulation. Figure 2 Hypothesized relationships among EPC types to mononuclear cell subtypes. Circulating angiogenic cells (CACs) comprise the largest population of EPC types, comparable in magnitude to circulating monocytes, which we hypothesize to include in the CAC population. We propose that hematopoietic progenitor cells (HPC) overlap with colony-forming unit -endothelial cells (CFU-ECs) to a degree that has yet to be determined, and that the CAC population does not overlap with the HPC population. We also propose that CD45 expression distinguishes hematopoietic from non-hematopoietic EPC populations. We further propose that the non-hematopoietic CEC population constitutes a much smaller fraction of mononuclear cells than do hematopoietic CAC and CFU-EC populations, and we propose that ECFC reside within the CEC population.
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